Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients.

[1]  G. Beck,et al.  Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[2]  P. Stock,et al.  Kidney and Pancreas Transplantation in the United States, 1998–2007: Access for Patients with Diabetes and End‐Stage Renal Disease , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  I. Holme,et al.  Cerebrovascular Events in Renal Transplant Recipients , 2009, Transplantation.

[4]  M. Safar,et al.  Arterial stiffness and renal transplantation. , 2008, Journal of hypertension.

[5]  C. Sommerer,et al.  Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients , 2008, Journal of hypertension.

[6]  C. Björkelund,et al.  Asymmetric Dimethylarginine Independently Predicts Fatal and Nonfatal Myocardial Infarction and Stroke in Women: 24-Year Follow-Up of the Population Study of Women in Gothenburg , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[7]  H. Valantine,et al.  Asymmetric Dimethylarginine and Cardiac Allograft Vasculopathy Progression: Modulation by Sirolimus , 2008, Transplantation.

[8]  Peter Stenvinkel,et al.  Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[9]  S. Yamagishi,et al.  Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease (Review Article) , 2007, Nephrology.

[10]  W. van Biesen,et al.  Arterial stiffness and wave reflections in renal transplant recipients. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  Frank Donnerstag,et al.  ADMA Increases Arterial Stiffness and Decreases Cerebral Blood Flow in Humans , 2006, Stroke.

[12]  J. Manitius,et al.  THE INFLUENCE OF CALCINEURIN INHIBITORS ON PULSE WAVE VELOCITY IN KIDNEY TRANSPLANT RECIPIENTS. , 2006, Renal failure.

[13]  G. Wolf,et al.  Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease – possible candidates for paradoxical epidemiology? , 2006, Amino Acids.

[14]  C. Baylis.  Arginine, arginine analogs and nitric oxide production in chronic kidney disease , 2006, Nature Clinical Practice Nephrology.

[15]  E. Çakır,et al.  Endothelial Functions Improve with Decrease in Asymmetric Dimethylarginine (ADMA) Levels after Renal Transplantation , 2005, Transplantation.

[16]  A. Hartmann,et al.  Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  Carmine Zoccali,et al.  Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. , 2005, Journal of the American Society of Nephrology : JASN.

[18]  F. Kronenberg,et al.  Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. , 2005, Journal of the American Society of Nephrology : JASN.

[19]  S. Bode-Böger,et al.  Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. , 2005, Journal of the American Society of Nephrology : JASN.

[20]  A. Jardine,et al.  Risk Factors for Reaching Renal Endpoints in the Assessment of Lescol in Renal Transplantation (ALERT) Trial , 2005, Transplantation.

[21]  R. Ferrari,et al.  Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. , 2003, Archives of biochemistry and biophysics.

[22]  C. Zoccali,et al.  ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. , 2003, Atherosclerosis. Supplements.

[23]  A. Szabó,et al.  Protection of wistar furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase. , 2003, Journal of the American Society of Nephrology : JASN.

[24]  I. Holme,et al.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial , 2003, The Lancet.

[25]  P. Tsao,et al.  Impaired Nitric Oxide Synthase Pathway in Diabetes Mellitus: Role of Asymmetric Dimethylarginine and Dimethylarginine Dimethylaminohydrolase , 2002, Circulation.

[26]  T. Nakagawa,et al.  Nitric oxide modulates vascular disease in the remnant kidney model. , 2002, The American journal of pathology.

[27]  R. Nijveldt,et al.  Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. , 2002, Analytical biochemistry.

[28]  P. Tsao,et al.  Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. , 2002, JAMA.

[29]  C. Zoccali,et al.  Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[30]  C. Zoccali,et al.  Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.

[31]  I. Holme,et al.  Effects of Fluvastatin on Cardiac Events in Renal Transplant Patients: ALERT (Assessment of Lescol® in Renal Transplantation) Study Design and Baseline Data , 2001, Journal of cardiovascular risk.

[32]  F. Schweitzer,et al.  Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. , 2001, Kidney international. Supplement.

[33]  B. Kasiske,et al.  Explained and unexplained ischemic heart disease risk after renal transplantation. , 2000, Journal of the American Society of Nephrology : JASN.

[34]  G. Remuzzi,et al.  Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[36]  J. Cooke,et al.  Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. , 1999, Circulation.

[37]  P. Tsao,et al.  Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. , 1998, Circulation.

[38]  A. Deng,et al.  Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. , 1992, The Journal of clinical investigation.

[39]  S. Moncada,et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.

[40]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[41]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[42]  H. Holdaas.  Preventing Cardiovascular Outcome in Patients with Renal Impairment , 2005, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[43]  S. Okuda,et al.  Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. , 1997, Hypertension.

[44]  R. Zatz,et al.  Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy. , 1995, Journal of the American Society of Nephrology : JASN.